Markets:

Overview

News

Currencies

International

Treasuries

DexCom, Inc. - Common Stock (NQ:DXCM)

69.83 +4.75 (+7.30%)

Streaming Delayed Price Updated: 3:52 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

46 47 Next >

Top S&P500 movers in Friday's session ↗

Today 15:05 EST

Via Chartmill

Friday's session: top gainers and losers in the S&P500 index ↗

Today 12:35 EST

Via Chartmill

Why Is DexCom (DXCM) Stock Rocketing Higher Today

Today 11:31 EST

Shares of medical device company DexCom (NASDAQ:DXCM) jumped 7.3% in the morning session after it reported better-than-expected fourth-quarter 2025 financial results, beating analyst estimates for both...

Via StockStory

Topics Artificial Intelligence Supply Chain

Soleus Adds a Significant Number of Celcuity Shares ↗

Today 7:54 EST

This clinical-stage biotech develops targeted cancer therapies and diagnostics using proprietary technology for personalized treatment.

Via The Motley Fool

Dexcom Inc (NASDAQ:DXCM) Beats Q4 Profit Estimates Despite Revenue Shortfall ↗

February 12, 2026

Via Chartmill

DexCom Inc. (NASDAQ:DXCM) Combines Strong Fundamentals with Bullish Chart Pattern ↗

January 20, 2026

Via Chartmill

DXCM Q4 Deep Dive: New Product Launches and International Strategy Drive Outlook

Today 0:35 EST

Medical device company DexCom (NASDAQ:DXCM) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 13.1% year on year to $1.26 billion. The company expects the full year’s...

Via StockStory

DexCom (DXCM) Q4 2025 Earnings Call Transcript ↗

February 12, 2026

DexCom (DXCM) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings Economy

DexCom (NASDAQ:DXCM) Exceeds Q4 CY2025 Expectations

February 12, 2026

Medical device company DexCom (NASDAQ:DXCM) announced better-than-expected revenue in Q4 CY2025, with sales up 13.1% year on year to $1.26 billion. The company expects the full year’s revenue to be...

Via StockStory

Dexcom Reports Fourth Quarter and Fiscal Year 2025 Financial Results

February 12, 2026

From DexCom, Inc.

Via Business Wire

Earnings To Watch: DexCom (DXCM) Reports Q4 Results Tomorrow

February 10, 2026

Medical device company DexCom (NASDAQ:DXCM) will be reporting earnings this Thursday after market hours. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

1 High-Flying Stock with Impressive Fundamentals and 2 We Ignore

February 08, 2026

"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated...

Via StockStory

1 Cash-Producing Stock Worth Your Attention and 2 Facing Headwinds

February 05, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

Stelo Adds Enhanced Smart Meal Logging Features as Dexcom Continues to Transform Personal Glucose Management

February 04, 2026

From Dexcom, Inc.

Via Business Wire

3 Profitable Stocks for Long-Term Investors

January 28, 2026

Profitability is a key measure of business strength. Companies with high margins have proven they can generate consistent earnings while maintaining financial discipline.

Via StockStory

Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time.

January 27, 2026

From DexCom, Inc.

Via Business Wire

2 Mid-Cap Stocks with Exciting Potential and 1 We Ignore

January 26, 2026

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...

Via StockStory

Abbott Laboratories Shares Plunge 10% Following Q4 Revenue Miss and Diagnostics Weakness

January 22, 2026

Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting...

Via MarketMinute

Topics Economy

Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat

January 22, 2026

Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an...

Via MarketMinute

Topics Earnings Economy

1 Growth Stock Down 19% to Buy Right Now ↗

January 21, 2026

It has had strong momentum since November, but there is still plenty of upside left.

Via The Motley Fool

Topics Product Recall

Halper Sadeh LLC Encourages DexCom, Inc. Shareholders to Contact the Firm to Discuss Their Rights

January 15, 2026

From Halper Sadeh LLC

Via Business Wire

Top S&P500 movers in Monday's session ↗

January 12, 2026

Via Chartmill

What's going on in today's session: S&P500 movers ↗

January 12, 2026

Via Chartmill

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

January 12, 2026

From DexCom, Inc.

Via Business Wire

DexCom (DXCM) Stock Trades Down, Here Is Why

January 08, 2026

Shares of medical device company DexCom (NASDAQ:DXCM) fell 2.6% in the morning session after analysts at Piper Sandler and Bernstein lowered their price targets on the stock, citing concerns over the...

Via StockStory

Topics Artificial Intelligence

Dexcom Enters Next Era of Continued Innovation With Jake Leach as President and Chief Executive Officer

January 07, 2026

From DexCom, Inc.

Via Business Wire

3 Nasdaq 100 Stocks Worth Your Attention

January 04, 2026

The Nasdaq 100 (^NDX) is where investors find some of the most innovative and disruptive companies shaping the future. A select few continue to execute at a high level, growing their market dominance...

Via StockStory

The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature

January 01, 2026

As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has...

Via PredictStreet

Topics Economy Lawsuit World Trade

2 Healthcare Stocks for Long-Term Investors and 1 We Find Risky

December 31, 2025

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, which has supported the...

Via StockStory

Topics Stocks

2 Growth Stocks to Buy For 2026 and Beyond ↗

December 30, 2025

Neither had a great year in 2025, but the future is looking bright.

Via The Motley Fool

Topics Economy

< Previous 1 2 3 4 5 6 7 8 9

...

46 47 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.